A study of the safety of Risperidone with Olanzapine in new psychosis patients

A comparative study of the safety of Risperidone with Olanzapine in patients of new-onset psychosis - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/07/071680

Enrollment

Registered

2024-07-31

Start date

Unknown

Completion date

Unknown

Last updated

2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G- Mental Health

Interventions

Intervention1: Risperidone: tab. risperidone 2 to 8 mg once daily will be given to patient orally for 6 months Control Intervention1: Olanzapine: tab. olanzapine 5 mg to 30 mg once daily will be given

Eligibility

Inclusion criteria

Inclusion criteria: All newly diagnosed adult patients of psychosis without any other co-morbidities. All newly diagnosed adult patients of psychosis who are willing to give consent.

Exclusion criteria

Exclusion criteria: Patients not willing to give written informed consent Pregnant females Patients already on treatment with study drugs Patients with known contra-indication or refractoriness to study drugs Patients with known history of heart disease Patients with known hypersensitivity to study drugs Patients with history of epilepsy & other neurological disorders Patients with a high risk of suicidal tendency

Design outcomes

Primary

Measure	Time frame
which drug is safer in terms of adverse effects.Timepoint: from baseline over a period 6 months	—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactDr Ashish Bansal

Dr.Rajendra Prasad Government Medical college

atalsood7@gmail.com9418063191

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026